Every Form 4 that ACM Research, Inc. (ACMR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACMR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACMR filings page.
ACM Research, Inc. (ACMR) reported that director, officer, and ten percent owner David H. Wang exercised options to acquire a total of 140,000 shares of Class A Common Stock at an exercise price of $1.00 per share on September 8 and 9, 2026, and sold 140,000 shares of Class A Common Stock in multiple open-market transactions on those same dates under a Rule 10b5-1 trading plan adopted on June 5, 2026.
ACM Research, Inc. (ACMR) reported that director Charles C. Pappis received equity awards on August 12, 2026. He was granted 6,400 stock options with an exercise price of $81.26 per share, expiring on August 11, 2036; these options vest and become exercisable immediately prior to the 2027 annual meeting of stockholders, subject to continued service. He also received 728 restricted stock units, with a reference price of $96.13 per unit based on the average closing price over the 30 trading days before the grant; these RSUs are scheduled to vest immediately prior to the 2027 annual meeting of stockholders, subject to continued service.
ACM Research, Inc. (ACMR) reported that director Tracy Liu received equity compensation awards. On 2026-08-12, Liu was granted stock options for 6,400 shares of Class A common stock at an exercise price of $81.26 per share, expiring on 2036-08-11. These options will vest and become exercisable immediately prior to the 2027 annual meeting of stockholders, subject to continued service through the vesting date.
On the same date, Liu was also granted 728 restricted stock units, each representing one share of Class A common stock. The price per restricted stock unit is based on the average closing market price of $96.13 for the issuer's common stock over the 30 trading days preceding the grant date. These restricted stock units are scheduled to vest immediately prior to the 2027 annual meeting of stockholders, subject to continued service.
ACM Research, Inc. (ACMR) reported that director Haiping Dun received new equity awards. On 2026-08-12, Dun was granted a stock option for 6,400 shares of Class A Common Stock at an exercise price of $81.26 per share, expiring on 2036-08-11. The option will vest and become exercisable immediately prior to the issuer’s 2027 annual stockholders meeting, subject to continued service. Dun also received 728 Restricted Stock Units, with the per-unit value based on the average closing price over the 30 trading days before the grant; these RSUs are scheduled to vest immediately prior to the 2027 annual meeting, subject to continued service.
ACM Research, Inc. (ACMR) reported that Chief Financial Officer and Treasurer Mark McKechnie exercised stock options for a total of 55,199 shares of Class A Common Stock on August 20, 2026, at exercise prices of $19.49 and $13.89 per share, from fully vested options. He then sold 55,199 shares in three transactions at weighted-average prices of $76.34, $77.45, and $77.89 per share, with the sales effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2026.
ACM Research, Inc. (ACMR) director Haiping Dun exercised stock options for 5,000 shares of Class A Common Stock at an exercise price of $5.60 per share, from a fully vested option, and on the same date sold 5,000 shares in multiple open-market transactions at weighted average prices between $79.89 and $82.33 pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. Following the option exercise, Dun held 45,000 stock options directly and reported indirect holdings of 100,000 shares in the Dun Family GST Trust and 755,090 shares in the Haiping Dun & Chi-Pin H Dun Revocable Trust.
Wang David H reported acquisition or exercise transactions in this Form 4 filing.
ACM Research, Inc. reported an insider equity award connected to director and officer David H. Wang. A trust for his daughter, Sophia Wang, received a grant of 6,208 restricted stock units tied to Class A common stock. Each restricted stock unit represents a contingent right to receive one share of ACMR common stock, with the grant value based on a 30-day lookback average fair market value of $51.54 per share. These units vest in four equal annual installments beginning on May 13, 2027. The filing also lists indirect holdings of Class A common stock by several family-related trusts and by Wang’s spouse and daughter.
ACM Research, Inc. insider activity: Officer Cheav Sotheara reported exercising stock options for 18,750 shares of Class A Common Stock at an exercise price of $13.89 per share and selling 18,750 shares in open-market transactions on June 4–5, 2026.
The sales were executed at reported prices generally in the low-to-mid $80s per share across multiple trades and were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, Sotheara directly holds 100,002 shares of ACM Research Class A Common Stock.
ACM Research, Inc. director and officer David H. Wang reported a mix of open-market sales and option exercises in Class A common stock. On June 3–4, he sold a total of 100,002 shares in multiple open-market transactions, including sales of 1,187 shares at $93.04 and 2,060 shares at $83.86 per share.
Over the same two days, Wang exercised stock options to acquire 100,002 shares of Class A common stock at a $1.00 per share exercise price, with the options fully vested and exercisable. Following these transactions, he holds 802,708 Class A shares directly, along with several indirect positions through family trusts and related accounts. The filing notes that the sales were made under a Rule 10b5-1 trading plan adopted on November 29, 2024, indicating the trades were pre-scheduled rather than discretionary.
ACM Research, Inc. director Haiping Dun reported a mix of option exercises and share sales in Class A Common Stock. On May 19, 2026, he exercised stock options for 5,000 shares at an exercise price of $5.60 per share, then sold 5,000 shares in multiple open-market transactions at prices between $63.84 and $67.54. The filing notes these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025. After these transactions, he reported no directly held Class A Common Stock, while indirect holdings include 755,090 shares held by the Haiping Dun & Chi-Pin H Dun Revocable Trust and 100,000 shares held by the Dun Family GST Trust.
ACM Research director Charles C. Pappis reported an option exercise paired with an open-market sale of shares. On April 17, 2026, he sold 5,000 shares of Class A Common Stock at $52.00 per share in an open-market transaction. That same day, he exercised a previously issued stock option covering 5,000 shares at an exercise price of $29.18 per share, and the option is now fully exercised. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 20, 2025, indicating the timing of the transaction was planned in advance.
ACM Research, Inc. officer Mark McKechnie exercised stock options and sold the resulting shares. He exercised options covering 98,551 shares of Class A common stock at exercise prices of $13.89 and $19.49 per share, then sold 98,551 shares in open-market transactions at weighted average prices in the mid-$40s. The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 27, 2025, indicating the transactions were scheduled in advance rather than timed discretionarily.
ACM Research insider David H. Wang, a director, officer and more than 10% owner, exercised stock options and sold shares of Class A Common Stock. On March 11–12, 2026, he exercised options for a total of 110,000 shares at an exercise price of $1.00 per share.
Over the same two days, Wang executed open-market sales totaling 110,000 shares at weighted average prices ranging from the mid‑$44 to high‑$48 range, under a pre-arranged Rule 10b5‑1 trading plan adopted on November 29, 2024. After these transactions, he held 802,708 shares directly, plus additional indirect holdings through family members and family trusts.
ACM Research, Inc. director Tracy Liu reported an exercise-and-sell transaction involving company stock. On March 10–11, 2026, Liu exercised stock options to acquire a total of 60,000 shares of Class A Common Stock at an exercise price of $1.00 per share. The same 60,000 shares were then sold in open-market transactions at weighted average prices within ranges from $46.67 to $48.50, under a pre-arranged Rule 10b5-1 trading plan adopted on December 4, 2025. After these transactions, Liu directly held 110,772 shares of Class A Common Stock.
ACM Research, Inc. director Haiping Dun exercised stock options for 5,000 shares of Class A Common Stock at $5.60 per share, then sold 5,000 shares in open-market transactions around $43–$44 per share. These sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025. Following the trades, Dun reported no direct Class A Common Stock holdings, while continuing to hold 55,000 stock options and indirect ownership of 100,000 and 755,090 Class A shares through family trusts.
ACM Research director Charles C. Pappis reported a stock option exercise and related share sale. On March 5, 2026, he exercised a previously issued option for 5,000 shares of Class A Common Stock, receiving the shares at an exercise price of $29.1800 per share.
That same day, he sold 5,000 shares of Class A Common Stock in an open-market transaction at $50.0900 per share, leaving him with 0 shares directly owned after the transactions. The sale was carried out under a pre-established Rule 10b5-1 trading plan adopted on November 20, 2025, and the option was fully vested and exercisable.
ACM Research, Inc. officer Lisa Feng exercised stock options and sold shares of Class A Common Stock. On March 5 and 6, 2026, she exercised options for a total of 30,000 shares of Class A Common Stock at an exercise price of $4.55 per share through derivative conversions.
Over those two days she sold a total of 30,000 shares of Class A Common Stock in open-market transactions at weighted average prices ranging from $45.51 to $50.54, under a Rule 10b5‑1 trading plan adopted on December 2, 2025. Following these transactions, she directly holds 50,001 shares of Class A Common Stock.
ACM Research CEO David H. Wang reported the vesting of performance-based stock options tied to the company’s market value. On February 4, 2026, 545,400 stock options with a $7.36 exercise price became exercisable, bringing his total outstanding options to 1,636,197 shares of Class A common stock.
The options were originally granted on March 20, 2020 and vest in three tranches when ACM Research’s market capitalization increases by $1 billion, $2 billion, and $3 billion from $553,383,586 at grant. The latest vesting was triggered when market capitalization first reached or exceeded $3,553,383,586. The filing also lists indirect holdings of Class A common stock through family members and family trusts.
ACM Research (ACMR) director Haiping Dun filed a Form 4 reporting a charitable-style transfer. On 11/12/2025, he made a gift of 755,090 shares of Class A common stock (transaction code G) at $0 to the Haiping Dun & Chi-Pin H Dun Revocable Trust, where he serves as co‑trustee and immediate family members are beneficiaries.
Following the transaction, reported holdings shifted to 0 shares direct and 755,090 shares indirect via the trust. This filing reflects a change in form of ownership, not an open-market sale.
ACM Research (ACMR): insider Form 4 shows option exercises and sales. An officer reported exercising 15,000 stock options at $5.60 on 11/12/2025 and another 15,000 at $5.60 on 11/13/2025. On the same dates, 15,000 shares were sold at $32.76 and 15,000 shares at $33.77, respectively.
The sales were made under a Rule 10b5-1 trading plan adopted on 08/13/2025. Following each day’s transactions, the filing lists 50,001 shares beneficially owned directly. The exercised options were fully vested and carry an expiration date of 04/22/2029.
ACM Research (ACMR) Form 4: CEO, President and Director David H. Wang reported vesting and acquisition of 545,400 stock options at an exercise price of $7.36 on October 27, 2025, from a 2020 performance grant. These options are now exercisable and expire on March 19, 2030.
The vesting occurred after the company’s market capitalization reached $2,553,383,586 under the grant’s formula; remaining tranches vest if market cap reaches $3,553,383,586. Indirect beneficial holdings disclosed include 620,001 shares (Wang‑Chen Family Living Trust), 180,000 (Family Irrevocable Trust for Wang Children), 100,002 (spouse), and 45,837 (daughter).
David H. Wang, CEO and Director of ACM Research, Inc. (ACMR), exercised 130,000 vested stock options by net exercise on 09/08/2025 at an exercise price of $1 per share. The filing shows the option was fully vested and the net exercise closed on that date, resulting in 610,002 shares held directly after the transaction. The report also discloses indirect holdings: 100,002 shares held by Jing Chen (his wife), 45,837 by his daughter Sophia Wang, 180,000 by a family trust for his children, and 620,001 by the Wang-Chen Family Living Trust. The Form 4 was signed by an attorney-in-fact on 09/30/2025.
Tracy Liu, a director of ACM Research, Inc. (ACMR), exercised 15,000 fully vested stock options on September 17, 2025, at a $1 exercise price, creating 15,000 shares of Class A common stock. The same day, the reporting person sold 15,000 shares at $33.00 per share pursuant to a Rule 10b5-1 trading plan adopted March 6, 2025. After these transactions, Ms. Liu beneficially owned 110,772 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Liu on September 19, 2025.
The reporting person, Jian Wang, exercised a fully vested stock option to acquire 30,000 shares of ACM Research Class A common stock at an exercise price of $5.60 per share and concurrently sold 30,000 shares under a Rule 10b5-1 trading plan at $35.00 per share. Following these transactions, the report shows beneficial ownership of 253,158 shares, down from 283,158 shares before the transactions.
The filing states the option was previously issued and fully exercisable and that the sales were effected pursuant to a 10b5-1 plan adopted on May 20, 2025. The form identifies the reporting person as an officer and notes an officer/subsidiary leadership role in ACM Research (Shanghai), Inc.
Insider activity at ACM Research (ACMR): Senior Vice President Sotheara Cheav exercised a stock option on 09/18/2025 to buy 10,000 shares of Class A common stock at an exercise price of $13.89 per share and simultaneously sold 10,000 shares at $35.00 per share under a Rule 10b5-1 trading plan adopted May 15, 2025. Following these transactions the reporting person beneficially owns 100,002 shares and holds options covering 56,250 underlying shares, with a portion of those options vesting through May 2026 and monthly thereafter. The Form 4 was signed on 09/19/2025 by an attorney-in-fact.